Profitability
This table compares SELLAS Life Sciences Group and CV Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SELLAS Life Sciences Group | N/A | -629.46% | -178.65% |
| CV Sciences | -16.24% | -101.85% | -29.04% |
Volatility and Risk
SELLAS Life Sciences Group has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, CV Sciences has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.
Institutional and Insider Ownership
17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 1.2% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 1.3% of CV Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SELLAS Life Sciences Group | $1.00 million | 99.02 | -$37.34 million | ($0.52) | -2.10 |
| CV Sciences | $16.00 million | 0.37 | $3.10 million | ($0.01) | -3.21 |
CV Sciences has higher revenue and earnings than SELLAS Life Sciences Group. CV Sciences is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.
Summary
CV Sciences beats SELLAS Life Sciences Group on 6 of the 11 factors compared between the two stocks.
About SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
About CV Sciences
CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
